Chemours
Market Cap
US$3.6b
Last Updated
2020/10/26 05:32 UTC
Data Sources
Company Financials +
Executive Summary
The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. More Details
Rewards
Risk Analysis
Snowflake Analysis
Reasonable growth potential second-rate dividend payer.
Similar Companies
Share Price & News
How has Chemours's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: CC's share price has been volatile over the past 3 months.
Market Performance
7 Day Return
-3.6%
CC
0.3%
US Chemicals
0.4%
US Market
1 Year Return
28.8%
CC
9.0%
US Chemicals
17.8%
US Market
Return vs Industry: CC exceeded the US Chemicals industry which returned 9% over the past year.
Return vs Market: CC exceeded the US Market which returned 17.8% over the past year.
Shareholder returns
| CC | Industry | Market | |
|---|---|---|---|
| 7 Day | -3.6% | 0.3% | 0.4% |
| 30 Day | 11.6% | 6.0% | 6.1% |
| 90 Day | 21.0% | 5.7% | 8.9% |
| 1 Year | 37.1%28.8% | 11.6%9.0% | 20.5%17.8% |
| 3 Year | -56.6%-61.6% | 15.2%-6.4% | 42.3%32.9% |
| 5 Year | 231.3%187.9% | 62.3%24.7% | 84.2%63.4% |
Price Volatility Vs. Market
How volatile is Chemours's share price compared to the market and industry in the last 5 years?
Simply Wall St News
3 days ago | Simply Wall St
Shareholders Of Chemours (NYSE:CC) Must Be Happy With Their 260% Total Return2 weeks ago | Simply Wall St
Here's Why Chemours (NYSE:CC) Is Weighed Down By Its Debt Load1 month ago | Simply Wall St
Here's What The Chemours Company's (NYSE:CC) Shareholder Ownership Structure Looks LikeValuation
Is Chemours undervalued compared to its fair value and its price relative to the market?
39.6%
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: CC ($21.88) is trading below our estimate of fair value ($36.22)
Significantly Below Fair Value: CC is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: CC is unprofitable, so we can't compare its PE Ratio to the US Chemicals industry average.
PE vs Market: CC is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate CC's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: CC is overvalued based on its PB Ratio (5.5x) compared to the US Chemicals industry average (2x).
Next Steps
Future Growth
How is Chemours forecast to perform in the next 1 to 3 years based on estimates from 7 analysts?
116.1%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: CC is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.2%).
Earnings vs Market: CC is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: CC's is expected to become profitable in the next 3 years.
Revenue vs Market: CC's revenue (6.1% per year) is forecast to grow slower than the US market (9.9% per year).
High Growth Revenue: CC's revenue (6.1% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: CC's Return on Equity is forecast to be very high in 3 years time (44.3%).
Next Steps
Past Performance
How has Chemours performed over the past 5 years?
21.0%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: CC is currently unprofitable.
Growing Profit Margin: CC is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: CC is unprofitable, but has reduced losses over the past 5 years at a rate of 21% per year.
Accelerating Growth: Unable to compare CC's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CC is unprofitable, making it difficult to compare its past year earnings growth to the Chemicals industry (-18.6%).
Return on Equity
High ROE: CC has a negative Return on Equity (-17.75%), as it is currently unprofitable.
Next Steps
Financial Health
How is Chemours's financial position?
Financial Position Analysis
Short Term Liabilities: CC's short term assets ($2.7B) exceed its short term liabilities ($1.2B).
Long Term Liabilities: CC's short term assets ($2.7B) do not cover its long term liabilities ($5.2B).
Debt to Equity History and Analysis
Debt Level: CC's debt to equity ratio (650.8%) is considered high.
Reducing Debt: CC's debt to equity ratio has reduced from 990.4% to 650.8% over the past 5 years.
Debt Coverage: CC's debt is not well covered by operating cash flow (19.7%).
Interest Coverage: CC is unprofitable, therefore interest payments are not well covered by earnings.
Balance Sheet
Next Steps
Dividend
What is Chemours's current dividend yield, its reliability and sustainability?
4.57%
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: CC's dividend (4.57%) is higher than the bottom 25% of dividend payers in the US market (1.63%).
High Dividend: CC's dividend (4.57%) is in the top 25% of dividend payers in the US market (4.56%)
Stability and Growth of Payments
Stable Dividend: Whilst dividend payments have been stable, CC has been paying a dividend for less than 10 years.
Growing Dividend: CC's dividend payments have increased, but the company has only paid a dividend for 5 years.
Current Payout to Shareholders
Dividend Coverage: CC is paying a dividend but the company is unprofitable.
Future Payout to Shareholders
Future Dividend Coverage: CC's dividends in 3 years are forecast to be well covered by earnings (32% payout ratio).
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
2.5yrs
Average management tenure
CEO
Mark Vergnano (62 yo)
5.25yrs
Tenure
US$7,695,644
Compensation
Mr. Mark P. Vergnano has been the Chief Executive Officer and President at The Chemours Company since July 01, 2015. Mr. Vergnano served as the Chief Executive Officer of Performance Chemicals at E. I. du ...
CEO Compensation Analysis
Compensation vs Market: Mark's total compensation ($USD7.70M) is above average for companies of similar size in the US market ($USD5.60M).
Compensation vs Earnings: Mark's compensation has been consistent with company performance over the past year.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 5.25yrs | US$7.70m | 0.46% $ 16.5m | |
| Senior VP & CFO | 1.33yrs | US$1.74m | 0.15% $ 5.5m | |
| Senior VP & COO | 1.33yrs | US$2.75m | 0.083% $ 3.0m | |
| Senior VP | 5.92yrs | US$1.68m | 0.067% $ 2.4m | |
| President of Titanium Technologies | 5.42yrs | US$1.75m | 0.086% $ 3.1m | |
| President of Chemical Solutions & Fluoroproducts | 2.5yrs | US$1.58m | 0.026% $ 939.4k | |
| VP, Chief Accounting Officer & Controller | 1.17yrs | no data | 0.013% $ 477.9k | |
| Vice President of Corporate Development & Investor Relations | 2.42yrs | no data | no data | |
| Senior VP of Corporate Communications & Chief Brand Officer | no data | no data | no data | |
| Senior Vice President of People & Health Services | no data | no data | 0.0078% $ 281.7k |
2.5yrs
Average Tenure
54.5yo
Average Age
Experienced Management: CC's management team is considered experienced (2.5 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 5.25yrs | US$7.70m | 0.46% $ 16.5m | |
| Independent Director | 5.25yrs | US$265.00k | 0.012% $ 446.3k | |
| Independent Chairman of the Board | 5.25yrs | US$355.00k | 0.012% $ 437.7k | |
| Independent Director | 5.25yrs | US$260.00k | 0.0028% $ 100.3k | |
| Independent Director | 5.25yrs | US$260.00k | 0.0029% $ 103.5k | |
| Independent Director | 5.25yrs | US$245.00k | 0.029% $ 1.0m | |
| Independent Director | 5.75yrs | US$245.00k | 0.029% $ 1.0m | |
| Independent Director | 2.42yrs | US$245.00k | 0.012% $ 442.0k | |
| Independent Director | 1.33yrs | US$195.00k | 0.013% $ 456.4k |
5.3yrs
Average Tenure
63yo
Average Age
Experienced Board: CC's board of directors are considered experienced (5.3 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
The Chemours Company's company bio, employee growth, exchange listings and data sources
Key Information
- Name: The Chemours Company
- Ticker: CC
- Exchange: NYSE
- Founded: 2014
- Industry: Diversified Chemicals
- Sector: Materials
- Market Cap: US$3.594b
- Shares outstanding: 164.24m
- Website: https://www.chemours.com
Number of Employees
Location
- The Chemours Company
- 1007 Market Street
- Wilmington
- Delaware
- 19801
- United States
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| CC | NYSE (New York Stock Exchange) | Yes | Common Stock | US | USD | Jun 2015 |
| CC * | BMV (Bolsa Mexicana de Valores) | Yes | Common Stock | MX | MXN | Jun 2015 |
| 2CU | DB (Deutsche Boerse AG) | Yes | Common Stock | DE | EUR | Jun 2015 |
| 0HWG | LSE (London Stock Exchange) | Yes | Common Stock | GB | USD | Jun 2015 |
Biography
The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. It operates through three segments: Fluoroproducts, Chemical Solu ...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2020/10/26 05:32 |
| End of Day Share Price | 2020/10/23 00:00 |
| Earnings | 2020/06/30 |
| Annual Earnings | 2019/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.